 |
|
|
| |
An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults
|
| |
| |
Reported by Jules Levin
IDWeek; San Francisco, CA; October 3-7, 2018
Melanie Thompson, MD1; Chloe Orkin, MBBCh2; Jean-Michel Molina, MD3; Paul Sax, MD4; Pedro Cahn, MD, PhD5; Kathleen Squires, MD6,7; Yan Zhou, PhD7; Xia Xu, PhD7*; Anthony Rodgers, MS7; Sushma Kumar, PhD, PMP7; Hedy Teppler, MD8; Elizabeth Martin, DO, MPH7; George Hanna, MD7; and Carey Hwang, MD, PhD7
1AIDS Research Consortium of Atlanta, Atlanta, GA; 2The Royal London Hospital, London, United Kingdom; 3Department of Infectious Diseases, Saint-Louis Hospital, Paris, France; 4Brigham and Women's Hospital, Boston, MA; 5Fundación Huésped, Buenos Aires, Argentina; 6Sidney Kimmel Medical College of Thomas Jefferson University Philadelphia, Philadelphia, PA; 7Merck & Co., Inc., Kenilworth, NJ; 8Merck & Co., Inc., Whitehouse Station, NJ
*At the time this research was conducted.
|
| |
|
|
|
|
|
